Increased Incidence of Stroke, but Not Coronary Heart Disease, in Elderly Patients With Sleep Apnea.

Background and Purpose- The influence of age on the relationship between obstructive sleep apnea (OSA) and the incidence of hard cardiovascular events remains controversial. We sought to analyze the relationship between OSA and the incidence of stroke and coronary heart disease in a large cohort of elderly patients, as well as to investigate the role of continuous positive airway pressure (CPAP) treatment in these associations. Methods- Post hoc analysis of a prospective observational study of consecutive patients ≥65 years studied for OSA suspicion at 2 Spanish University Hospitals. Patients with an apnea-hypopnea index (AHI) <15 were the reference group. OSA was defined by an AHI ≥15 and classified as untreated (CPAP not prescribed or compliance <4 hours/day), mild-moderate (AHI 15-29), untreated severe (AHI ≥30), and CPAP-treated (AHI ≥15 and CPAP compliance ≥4 hours/day). Results- 859 and 794 elderly patients were included in the stroke and coronary heart disease analyses, respectively. The median (interquartile range) follow-up was 72 (50-88.5) and 71 (51.5-89) months, respectively. Compared with the reference group, the fully adjusted hazard ratios for the incidence of stroke were 3.42 (95% CI, 1.37-8.52), 1.02 (95% CI, 0.41-2.56), and 1.76 (95% CI, 0.62-4.97) for the untreated severe OSA group, CPAP-treated group, and untreated mild-moderate OSA group, respectively. No associations were shown between any of the different OSA groups and coronary heart disease incidence. Conclusions- The incidence of stroke, but not coronary heart disease, is increased in elderly patients with untreated severe OSA. Adequate CPAP treatment may reduce this risk.

OPENCRONIC Study. Knowledge and Experiences of Spanish Patients and Carers about Chronic Disease.

Background: Chronic diseases are currently the main cause of morbidity and mortality and represent a major challenge to healthcare systems. The objective of this study is to know Spanish public opinion about chronic disease and how it affects their daily lives. Methods: Through a telephone or online survey of 24 questions, data was gathered on the characteristics of the respondents and their knowledge and experiences of chronic diseases. Results: Of the 2522 survey respondents, 325 had a chronic disease and were carers, 1088 had a chronic disease and were not carers, 140 did not have a chronic disease but were carers, and 969 did not have chronic disease and were not carers. The degree of knowledge on these diseases was good or very good for 69.4%, 56.0%, 62.2%, and 46.7%, respectively, for each group. All the groups agreed that chronic diseases mainly affect mood, quality of life and having to make sacrifices. Conclusions: Knowledge about chronic diseases is relatively good, although it can be improved among the Spanish population, especially among patients who report having a chronic disease and play the role of carers. However, it is important to continue maintaining the level of information and training concerning these diseases.

Unanswered clinical questions in the management of cardiometabolic risk in the elderly: a statement of the Spanish Society of Internal Medicine.

BACKGROUND: Despite the progressive increase in life expectancy and the relationship between aging with multi-morbidities and the increased use of healthcare resources, current clinical practice guidelines (CPG) on cardiometabolic risk cannot be adequately applied to elderly subjects with multiple chronic conditions. Its management frequently becomes complicated by both, an excessive use of medications that may lead to overtreatment, drug interactions and increased toxicity, and errors in dosage and non-compliance. Concerned by this gap, the Spanish Society of Internal Medicine created a group of independent experts on cardiometabolic risk who discussed what they considered to be unanswered questions in the management of elderly patients. DISCUSSION: Current guidelines do not specifically address the problem of elderly with multiple chronic conditions. For this reason, the combined use of the limited available evidence, clinical experience and common sense, could all help us to address this unmet need. In very old people, life expectancy and functionality are the most important factors for guiding potential treatments. Their higher propensity to develop serious adverse events and their shorter lifespan could prevent them from obtaining the potential benefits of the interventions administered. SUMMARY: In this document, experts on cardiometabolic risk factors have established a number of consensual recommendations that have taken into account international guidelines and clinical experience, and have also considered the more effective use of healthcare resources. This document is intended to provide general recommendations for clinicians and to promote the effective use of procedures and medications.

Consistencia interna y validez de la versión española del cuestionario de calidad de vida específico para el síndrome de apnea del sueño: Sleep Apnoea Quality of Life Index / Internal Consistency and Validity of the Spanish Version of the Quality of Life Questionnaire Specific for Obstructive Sleep Apnea: Sleep Apnea Quality of Life Index

Introducción: El objetivo del presente estudio fue validar la versión española del Sleep Apnea Quality of Life Index (SAQLI), cuestionario de calidad de vida relacionada con la salud (CVRS) específico para el síndrome de apneas-hipopneas del sueño (SAHS), y evaluar su sensibilidad al cambio. Material y métodos: Estudio multicéntrico en un grupo de pacientes diagnosticados de SAHS (índice de apnea/hipopnea [IAH] ≥5) enviados a las unidades de sueño. En todos los pacientes se administraron los cuestionarios: SF-36, FOSQ, SAQLI y test de Epworth. Se evaluaron las propiedades psicométricas (consistencia interna, validez de constructo, validez concurrente, validez predictora, fiabilidad test-retest y sensibilidad al cambio) del cuestionario SAQLI (4 dominios: funcionamiento diario, interacciones sociales, funcionamiento emocional y síntomas; dispone de un quinto opcional: síntomas relacionados con el tratamiento). Resultados: Se incluyeron 162 pacientes (media de edad: 58±12 años; Epworth: 10±4; IMC: 33±5,9kg m−2; IAH: 37±15h−1). El análisis factorial mostró un constructo de 4 factores, distribuidos de manera similar a los dominios del cuestionario original. La consistencia interna (alfa de Cronbach entre 0,78 y 0,82 para los distintos dominios), la validez concurrente con respecto al SF-36, Epworth y FOSQ, así como la fiabilidad test-retest, fueron adecuadas. La validez predictora del cuestionario no mostró correlaciones significativas por gravedad de SAHS. El SAQLI mostró una buena sensibilidad al cambio en todos los dominios que componen el cuestionario (p<0,01). Conclusiones: La versión española del SAQLI presenta características psicométricas adecuadas para su utilización en pacientes con SAHS y es sensible al cambio(AU)

Introduction: The objective of the present study was to validate the Spanish version of the SAQLI, which is a health-related quality of life (HRQL) questionnaire specific for sleep apnea-hypopnea syndrome (SAHS), and to assess its sensitivity to change. Material and methods: A multicenter study performed in a group of patients with SAHS (apnea-hypopnea index [AHI] ≥5) who had been referred to the centers’ Sleep Units. All patients completed the following questionnaires: SF-36, FOSQ, SAQLI and Epworth scale. The psychometric properties (internal consistency, construct validity, concurrent validity, predictive value, repeatability and responsiveness to change) of the SAQLI were assessed (four domains: daily function, social interactions, emotional function and symptoms; an optional fifth domain is treatment-related symptoms). Results: One hundred sixty-two patients were included for study (mean age: 58±12; Epworth: 10±4; BMI: 33±5.9kg m−2; AHI: 37±15hour−1). The factorial analysis showed a construct of four factors with similar distribution to the original questionnaire domains. Internal consistency (Cronbach's alpha between 0.78 and 0.82 for the different domains), concurrent validity for SF-36, Epworth scale and FOSQ, and test-retest reliability were appropriate. The predictive validity of the questionnaire showed no significant correlations with the severity of SAHS. SAQLI showed good sensitivity to change in all the domains of the questionnaire (p<0,01). Conclusions: The Spanish version of the SAQLI is a valid HRQL measurement with appropriate psychometric properties for use in patients with SAHS and it is sensitive to change(AU)

El reto de la atención al paciente crónico complejo. El papel del internista / No disponible

No disponible

Internal consistency and validity of the Spanish version of the quality of life questionnaire specific for obstructive sleep apnea: sleep apnea quality of life index.

INTRODUCTION: The objective of the present study was to validate the Spanish version of the SAQLI, which is a health-related quality of life (HRQL) questionnaire specific for sleep apnea-hypopnea syndrome (SAHS), and to assess its sensitivity to change. MATERIAL AND METHODS: A multicenter study performed in a group of patients with SAHS (apnea-hypopnea index [AHI] ≥5) who had been referred to the centers' Sleep Units. All patients completed the following questionnaires: SF-36, FOSQ, SAQLI and Epworth scale. The psychometric properties (internal consistency, construct validity, concurrent validity, predictive value, repeatability and responsiveness to change) of the SAQLI were assessed (four domains: daily function, social interactions, emotional function and symptoms; an optional fifth domain is treatment-related symptoms). RESULTS: One hundred sixty-two patients were included for study (mean age: 58±12; Epworth: 10±4; BMI: 33±5.9kg m(-2); AHI: 37±15hour(-1)). The factorial analysis showed a construct of four factors with similar distribution to the original questionnaire domains. Internal consistency (Cronbach's alpha between 0.78 and 0.82 for the different domains), concurrent validity for SF-36, Epworth scale and FOSQ, and test-retest reliability were appropriate. The predictive validity of the questionnaire showed no significant correlations with the severity of SAHS. SAQLI showed good sensitivity to change in all the domains of the questionnaire (p<0,01). CONCLUSIONS: The Spanish version of the SAQLI is a valid HRQL measurement with appropriate psychometric properties for use in patients with SAHS and it is sensitive to change.

Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis.

BACKGROUND: The aim of this study is to evaluate the efficacy and safety of medium-dose formoterol-budesonide combined inhaled treatment in a single inhaler compared with high-dose budesonide treatment in patients with non-cystic fibrosis (non-CF) bronchiectasis. METHODS: This is a 12-month randomized, double-blind, parallel-groups clinical trial, to run in 40 patients with non-CF bronchiectasis diagnosed by high-resolution CT scan of the chest, receiving formoterol-budesonide combined treatment (18/640 µg daily) or budesonide treatment (1,600 µg daily). Variables concerning clinical condition, health-related quality of life (HRQL), lung function, ß(2)-adrenergic agonist use, potentially pathogenic microorganism (PPM) isolates, and medication side effects were analyzed by intention-to-treat analysis. RESULTS: The study group receiving a formoterol-budesonide combined treatment showed a significant improvement, both clinically and statistically, of symptoms (dyspnea, number of coughs, and rescue ß(2)-adrenergic agonist-free days). Furthermore, we observed an HRQL improvement, with no changes in functional parameters or in PPM isolates, together with an important reduction in overall side effects, especially for those related to inhaled steroids, compared with the high-dose budesonide treatment group. CONCLUSIONS: Inhaled medium-dose formoterol-budesonide combined treatment in a single inhaler is more effective and safe compared with high-dose budesonide treatment in patients with non-CF bronchiectasis. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00728715; URL: www.clinicaltrials.gov.

Continuous positive airway pressure treatment reduces mortality in patients with ischemic stroke and obstructive sleep apnea: a 5-year follow-up study.

RATIONALE: Obstructive sleep apnea (OSA) is an independent risk factor for stroke, but little is known about the role of continuous positive airway pressure (CPAP) on mortality in patients with stroke. OBJECTIVES: To analyze the independent impact of long-term CPAP treatment on mortality in patients with ischemic stroke. METHODS: Prospective observational study in 166 patients with ischemic stroke. Sleep study was performed in all of them and CPAP treatment was offered in the case of moderate to severe cases. Patients were followed-up for 5 years to analyze the risk of mortality. MEASUREMENTS AND MAIN RESULTS: Of 223 patients consecutively admitted for stroke, a sleep study was performed on 166 of them (2 mo after the acute event). Thirty-one had an apnea-hypopnea index (AHI) of less than 10; 39 had an AHI between 10 and 19, and 96 had an AHI of 20 or greater. CPAP treatment was offered when AHI was 20 or greater. Patients were followed up in our outpatient clinic at 1, 3, and 6 months, and for every 6 months thereafter for 5 years (prospective observational study). Mortality data were recorded from our computer database and official death certificates. The mean age of subjects was 73.3 +/- 11 years (59% males), and the mean AHI was 26 (for all patients with a predominance of obstructive events). Patients with an AHI of 20 or greater who did not tolerate CPAP (n = 68) showed an increase adjusted risk of mortality (hazards ratio [HR], 2.69; 95% confidence interval [CI], 1.32-5.61) compared with patients with an AHI of less than 20 (n = 70), and an increased adjusted risk of mortality (HR, 1.58; 95% CI, 1.01-2.49; P = 0.04) compared with patients with moderate to severe OSA who tolerated CPAP (n = 28). There were no differences in mortality among patients without OSA, patients with mild disease, and patients who tolerated CPAP. CONCLUSIONS: Our results suggest that long-term CPAP treatment in moderate to severe OSA and ischemic stroke is associated with a reduction in excess risk of mortality.

[The association between bronchiectasis, systemic inflammation, and tumor necrosis factor alpha]. / Bronquiectasias, inflamación sistémica y factor de necrosis tumoral alfa: factores asociados.

OBJECTIVE: The relationship between systemic inflammation and different measures of bronchiectasis severity has not been described. The objective of this study was to analyze the relationship between plasma concentrations of tumor necrosis factor alpha (TNF-alpha), as a marker of systemic inflammation, and some commonly used criteria for quantifying bronchiectasis severity in clinically stable patients whose disease was not caused by cystic fibrosis. PATIENTS AND METHODS: Sixty-eight clinically stable patients with bronchiectasis and 19 age- and sex-matched healthy control subjects were included in the study. Data on disease history, symptoms, severity, functional variables, sputum volume, and microbiological cultures, laboratory findings, and other indicators of disease course were collected. Plasma concentrations of TNF-alpha were measured using high-resolution enzyme-linked immunoabsorbent assay. RESULTS: Plasma concentrations of TNF-alpha were higher in patients than controls (8.28 vs 5.67 pg/mL; P=.001). This observation correlated with other markers of systemic inflammation such as erythrocyte sedimentation rate (r=0.42; P=.001), C-reactive protein (rho=0.45; P=.001), and percentage of peripheral blood neutrophils (rho=0.45; P=.001). Patients with high plasma concentrations of TNF-alpha (>8.1 pg/dL) had more severe disease (5.19 vs 3.21; P=.001), were more likely to have respiratory failure (37.5% vs 8.3%; P=.003), and a higher rate of Pseudomonas aeruginosa colonization (34.3% vs 8.3%; P=.008). CONCLUSIONS: High plasma concentrations of TNF-alpha were associated with several criteria usually used to assess severity of bronchiectasis in clinically stable patients with disease not caused by cystic fibrosis.

[Efficacy of a training program on sleep apnea-hypopnea syndrome aimed at primary care physicians]. / Eficacia de un plan de formación en atención primaria sobre el síndrome de apneas-hipopneas durante el sueño.

OBJECTIVE: The level of clinical suspicion of sleep apnea-hypopnea syndrome (SAHS) among primary care physicians is low. The aim of this study was to analyze the impact of a primary care training program on the quality and quantity of referrals made due to suspected SAHS. MATERIAL AND METHODS: A group of 16 primary care physicians were offered the option of participating in a training program consisting of 2 talks-workshops, the provision of up-to-date information on SAHS and a form for making referrals according to an established protocol, and the opportunity to contact the sleep department at our hospital directly. Twenty-one primary care physicians who did not receive training served as the control group. We gathered data on the quantity and quality of referrals made by both groups for the period January through June 2005 and 2006, and recorded the number of both SAHS diagnoses made and patients prescribed treatment with continuous positive airway pressure. Data were analyzed in function of the primary care population assigned to each group. RESULTS: The training program was completed by 81.3% of the physicians. The number of referrals made by the training group increased 2.38-fold after the program (intergroup comparison, P=.0001). There was also a 2.36-fold increase in the percentage of cases of SAHS detected in the population (P=.0008), a 1.85-fold increase in the percentage of serious cases detected (P=.001), and a 2-fold increase in the number of patients prescribed continuous positive airway pressure (P=.009). Agreement between the data gathered by the physicians and the sleep specialist was significantly higher in the training group for all the items studied. CONCLUSIONS: The implementation of a training program on SAHS aimed at primary care physicians improved both the quantity and quality of referrals made due to suspected SAHS.

Bronquiectasias, inflamación sistémica y factor de necrosis tumoral alfa: factores asociados / The association between bronchiectasis, systemic inflammation, and tumor necrosis factor alpha

Objetivo: La relación existente entre la presencia de inflamación sistémica y los diferentes parámetros de gravedad en pacientes con bronquiectasias no ha sido descrita. El objetivo del estudio ha sido analizar la relación entre las concentraciones plasmáticas de factor de necrosis tumoral alfa (pTNF-alfa), como marcador de inflamación sistémica, y algunos criterios de gravedad comúnmente utilizados en pacientes con bronquiectasias, en fase de estabilidad clínica, no debidas a fibrosis quística. Pacientes y métodos: Se incluyó en el estudio a 68 pacientes con bronquiectasias clínicamente estables y 19 controles sanos ajustados según edad y sexo. Se recogieron datos referentes a antecedentes patológicos, síntomas, extensión, variables funcionales, volumen de esputo y aspectos microbiológicos, analíticos y evolutivos. Las concentraciones de pTNF-alfa se analizaron utilizando un método de enzimoinmunoanálisis de alta resolución. Resultados: Se observó una mayor concentración de pTNF-alfa en los pacientes que en los controles (8,28 frente a 5,67 pg/ml; p = 0,001), que se correlacionó con otros parámetros de inflamación sistémica como la velocidad de sedimentación globular (r = 0,42; p = 0,001), la proteína C reactiva (r = 0,45; p = 0,001) y el porcentaje de neutrófilos periféricos (r = 0,45; p = 0,001). Los pacientes con concentraciones elevadas de pTNF-alfa (> 8,1 pg/dl) presentaron mayor extensión de la enfermedad (5,19 frente a 3,21; p = 0,001), mayor probabilidad de presentar insuficiencia respiratoria (el 37,5 frente al 8,3%; p = 0,003) y mayor porcentaje de colonizaciones por Pseudomonas aeruginosa (el 34,3 frente al 8,3%; p = 0,008). Conclusiones: Las concentraciones elevadas de pTNF-alfa se asocian a varios parámetros comúnmente utilizados para valorar la gravedad en pacientes con bronquiectasias clínicamente estables y no debidas a fibrosis quística

Objective: The relationship between systemic inflammation and different measures of bronchiectasis severity has not been described. The objective of this study was to analyze the relationship between plasma concentrations of tumor necrosis factor alpha (TNF-alpha), as a marker of systemic inflammation, and some commonly used criteria for quantifying bronchiectasis severity in clinically stable patients whose disease was not caused by cystic fibrosis. Patients and methods: Sixty-eight clinically stable patients with bronchiectasis and 19 age- and sex-matched healthy control subjects were included in the study. Data on disease history, symptoms, severity, functional variables, sputum volume, and microbiological cultures, laboratory findings, and other indicators of disease course were collected. Plasma concentrations of TNF-alpha were measured using high-resolution enzyme-linked immunoabsorbent assay. Results: Plasma concentrations of TNF-alpha were higher in patients than controls (8.28 vs 5.67 pg/mL; P=.001). This observation correlated with other markers of systemic inflammation such as erythrocyte sedimentation rate (r=0.42; P=.001), C-reactive protein (ñ=0.45; P=.001), and percentage of peripheral blood neutrophils (ñ=0.45; P=.001). Patients with high plasma concentrations of TNF-alpha (>8.1 pg/dL) had more severe disease (5.19 vs 3.21; P=.001), were more likely to have respiratory failure (37.5% vs 8.3%; P=.003), and a higher rate of Pseudomonas aeruginosa colonization (34.3% vs 8.3%; P=.008). Conclusions: High plasma concentrations of TNF-alpha were associated with several criteria usually used to assess severity of bronchiectasis in clinically stable patients with disease not caused by cystic fibrosis

Eficacia de un plan de formación en atención primaria sobre el síndrome de apneas-hipopneas durante el sueño / Efficacy of a training program on sleep apnea hypopnea syndrome aimed at primary care physicians

Objetivo: El grado de sospecha clínica del síndrome de apneas-hipopneas durante el sueño (SAHS) entre los médicos de atención primaria (MAP) es bajo. El propósito del presente trabajo ha sido analizar el impacto de un plan de formación dirigido a los MAP en la calidad y cantidad de las derivaciones realizadas por sospecha de SAHS. Material y métodos: Se ofreció a un grupo de 16 MAP un plan de formación consistente en 2 charlas-talleres, información actualizada sobre SAHS, una hoja de derivación protocolizada y contacto directo con la Unidad de Sueño. Un grupo de 21 MAP no formados sirvió como grupo control. Desde enero a junio de 2005 y 2006 se recogieron de ambos grupos datos referentes a la cantidad y calidad de las derivaciones realizadas según la población asignada a cada grupo, así como diagnósticos de SAHS y número de tratamientos prescritos con presión positiva continua de la vía aérea. Resultados: El 81,3% de los MAP siguió el plan de formación. El porcentaje de población asignada que fue derivada a la Unidad de Sueño aumentó en 2,38 veces tras el plan de formación en el grupo que la recibió (p intergrupos = 0,0001). Hubo un incremento de 2,36 veces en el porcentaje de población diagnosticada de SAHS (p intergrupos = 0,008), de 1,85 veces en SAHS graves (p intergrupos = 0,001) y de 2 veces en tratamientos prescritos con presión positiva continua de la vía aérea (p intergrupos = 0,009). La concordancia entre la información recogida por los MAP y por el especialista mejoró de forma significativa en todos los ítems estudiados. Conclusiones: La implantación de un plan de formación sobre SAHS dirigido a MAP resultó eficaz en la mejora de la cantidad y calidad de las derivaciones realizadas por sospecha de SAHS

Objective: The level of clinical suspicion of sleep apnea­hypopnea syndrome (SAHS) among primary care physicians is low. The aim of this study was to analyze the impact of a primary care training program on the quality and quantity of referrals made due to suspected SAHS. Material and Methods: A group of 16 primary care physicians were offered the option of participating in a training program consisting of 2 talks­workshops, the provision of up-to-date information on SAHS and a form for making referrals according to an established protocol, and the opportunity to contact the sleep department at our hospital directly. Twenty-one primary care physicians who did not receive training served as the control group. We gathered data on the quantity and quality of referrals made by both groups for the period January through June 2005 and 2006, and recorded the number of both SAHS diagnoses made and patients prescribed treatment with continuous positive airway pressure. Data were analyzed in function of the primary care population assigned to each group. Results: The training program was completed by 81.3% of the physicians. The number of referrals made by the training group increased 2.38-fold after the program (intergroup comparison, P=.0001). There was also a 2.36-fold increase in the percentage of cases of SAHS detected in the population (P=.0008), a 1.85-fold increase in the percentage of serious cases detected (P=.001), and a 2-fold increase in the number of patients prescribed continuous positive airway pressure (P=.009). Agreement between the data gathered by the physicians and the sleep specialist was significantly higher in the training group for all the items studied. Conclusions: The implementation of a training program on SAHS aimed at primary care physicians improved both the quantity and quality of referrals made due to suspected SAHS

[Bronchiectasis in the elderly. Study of serum levels of immunoglobulin G subclasses]. / Bronquiectasias en pacientes mayores de 65 años. Estudio de los valores séricos de las subclases de inmunoglobulina G.

BACKGROUND AND OBJECTIVE: To analyze the serum levels of immunoglobulin G (IgG) subclasses in a broad range of elderly patients with bronchiectasis. PATIENTS AND METHOD: Data were collected from all patients who had a high-resolution chest computerized axial tomography diagnosis of bronchiectasis in our center. We gathered data related to case history, respiratory symptoms, forced spirometry, general laboratory tests, immunoglobulin concentration (including IgG subclasses), Mantoux test, sputum culture and staining, paranasal sinus X-rays/computerized axial tomography, and a specific etiologic evaluation based on the available clinical evidence. RESULTS: A total of 128 patients were included -mean age (standard deviation): 71.6 (5.1) years; range: 65-88; 44.5% males- and 20.3% of them had chronic sputum colonization with Pseudomonas aeruginosa. 28.1% cases had a post-infectious nature and in 40.6% the etiology was unknown. Sixteen patients (12.5%) had decreased levels of at least one of the sIgG compared to normal values. The most frequent deficiency corresponded to IgG2 levels. These subjects showed a characteristic profile of bronchiectasis with an increased lung extension of the disease (p = 0.02); greater presence of cylindrical and diffuse bronchiectasis (p = 0.02 and 0.01, respectively), greater percentage of an unknown etiology (p = 0.004); greater presence of paranasal sinus X-ray abnormalities (p = 0.004) and increased number of past repeated upper airway infections (p = 0.03). CONCLUSIONS: Decreased serum levels of IgG subclasses might be associated with a characteristic profile of bronchiectasis in elderly patients in whom other etiologies have been ruled out.

Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis.

BACKGROUND: Bronchiectasis remains a major public health problem, but factors influencing its natural history are not well characterized. The objective of our study was to explore modifiable and nonmodifiable factors associated with lung function decline in a clinical cohort of patients with stable non-cystic fibrosis (CF) bronchiectasis. METHODS: Seventy-six stable adult patients (mean age, 69.9 years; 48.7% men) with bronchiectasis were included. The diagnosis of bronchiectasis was established in all cases by high-resolution CT scanning. Baseline data were collected on clinical history, symptoms, disease extension, treatment, sputum volume, microbiological aspects, laboratory findings, and exacerbations. All patients were invited to attend the clinic every 6 months for 24 months to conduct full spirometry and microbiological analysis of sputum, and to report the number of exacerbations. RESULTS: Overall, the group experienced a rate of decline of lung function (FEV1) of 52.7 mL per year. Independent factors associated with an accelerated decline of lung function were chronic colonization with Pseudomonas aeruginosa (PA) [odds ratio (OR), 30.4; 95% confidence interval (CI), 3.8 to 39.4; p=0.005], more frequent severe exacerbations (OR, 6.9; 95% CI, 2.3 to 10.5; p=0.014), and more systemic inflammation (OR, 3.1; 95% CI, 1.9 to 8.9; p=0.023). Regrettably, none of the long-term treatment strategies evaluated, including the use of long-acting inhaled bronchodilators, inhaled or oral steroids, oxygen therapy, secretion clearance maneuvers, or antibiotics had a significant effect on FEV1 decline. CONCLUSION: Chronic colonization by PA, severe exacerbations, and systemic inflammation are associated with disease progression in non-CF bronchiectasis.

Bronquiectasias en pacientes mayores de 65 años. Estudio de los valores séricos de las subclases de inmunoglobulina G / Bronchiectasis in the elderly. Study of serum levels of immunoglobulin G subclasses

Fundamento y objetivo: Analizar los valores séricos de las subclases de inmunoglobulina G (IgG) en un amplio número de pacientes mayores de 65 años con bronquiectasias. Pacientes y método: De todos los pacientes mayores de 65 años diagnosticados en nuestro centro de bronquiectasias mediante tomografía computarizada de alta resolución de tórax, se recogieron de forma prospectiva datos relativos a la historia clínica, síntomas, espirometría forzada, estudio analítico, determinación de la concentración de inmunoglobulinas, incluidas las subclases de IgG, Mantoux, tinción y cultivo de esputo, radiografía/tomografía computarizada de senos paranasales y estudio etiológico específico según sospecha clínica. Resultados: Se incluyó en el estudio a 128 pacientes, con una edad media (desviación estándar) de 71,6 (5,1) años (extremos: 65-88 años); un 44,5% eran varones. El 20,3% presentó colonización crónica por Pseudomonas aeruginosa. La causa conocida más frecuente de bronquiectasias fue la infecciosa (28,1%), si bien el 40,6% permaneció con etiología desconocida. Dieciséis pacientes (12,5%) presentaron alguna disminución de los valores séricos de las subclases de IgG respecto a los valores de normalidad, siendo la más frecuente la disminución de los valores de IgG2. Estos pacientes mostraron un perfil de bronquiectasias peculiar: de forma significativa, presentaron una mayor extensión pulmonar (p = 0,02), mayor porcentaje de formas difusas y cilíndricas (p = 0,02 y 0,01, respectivamente), mayor porcentaje de formas con etiología no conocida (p = 0,004), mayor afectación de los senos paranasales (p = 0,004) y mayor prevalencia pasada de infecciones respiratorias de las vías altas de repetición (p = 0,03). Conclusiones: La disminución de los valores séricos de las subclases de IgG podría asociarse a la aparición de bronquiectasias con un perfil peculiar en pacientes mayores de 65 años en los que se ha descartado otra posible causa

Background and objective: To analyze the serum levels of immunoglobulin G (IgG) subclasses in a broad range of elderly patients with bronchiectasis. Patientes and method: Data were collected from all patients who had a high-resolution chest computerized axial tomography diagnosis of bronchiectasis in our center. We gathered data related to case history, respiratory symptoms, forced spirometry, general laboratory tests, immunoglobulin concentration (including IgG subclasses), Mantoux test, sputum culture and staining, paranasal sinus X-rays/computerized axial tomography, and a specific etiologic evaluation based on the available clinical evidence. Results: A total of 128 patients were included ­mean age (standard deviation): 71.6 (5.1) years; range: 65-88; 44.5% males­ and 20.3% of them had chronic sputum colonization with Pseudomonas aeruginosa. 28.1% cases had a post-infectious nature and in 40.6% the etiology was unknown. Sixteen patients (12.5%) had decreased levels of at least one of the sIgG compared to normal values. The most frequent deficiency corresponded to IgG2 levels. These subjects showed a characteristic profile of bronchiectasis with an increased lung extension of the disease (p = 0.02); greater presence of cylindrical and diffuse bronchiectasis (p = 0.02 and 0.01, respectively), greater percentage of an unknown etiology (p = 0.004); greater presence of paranasal sinus X-ray abnormalities (p = 0.004) and increased number of past repeated upper airway infections (p = 0.03) Conclusions: Decreased serum levels of IgG subclasses might be associated with a characteristic profile of bronchiectasis in elderly patients in whom other etiologies have been ruled out

Improvement in nocturnal disordered breathing after first-ever ischemic stroke: role of dysphagia.

STUDY OBJECTIVE: The aim of this study was to analyze the role of dysphagia as a model of pharyngeal muscle dysfunction in the time course of nocturnal disordered breathing (NDB) in patients who experienced a first-ever ischemic stroke. DESIGN: Prospective study. PATIENTS AND INTERVENTIONS: Fifty-nine consecutive patients (mean age, 73.2 years; SD, 12.8 years) were studied. Clinical sleep and neurologic data and vascular risk factors were recorded. Two nocturnal studies using a portable autotitration device (AutoSet Portable Plus II system; ResMed; Sydney, NSW, Australia) were performed in both the acute phase (mean duration, 1.23 days; SD, 0.7 day) and the stable phase (mean duration 65.9 days; SD, 12.5 days) of the neurologic event in all patients. RESULTS: The mean total apnea-hypopnea index (AHI) measured with the autotitration device in the acute phase was 34.9 (SD, 25.2) vs 20.1 (SD, 21.7) in the stable phase, both with predominance of obstructive apnea. Patients with dysphagia (n = 30) showed the largest number of obstructive apneic episodes (OAIs) in the acute phase (AHI, 40 episodes; OAI, 30.4 episodes), with a significant reduction in this type of apnea during the stable phase of stroke (AHI, 24.7 episodes; OAI, 17.7 episodes), coinciding with the recovery of pharyngeal muscle function. In contrast, nondysphagic patients (n = 29) showed no significant changes in NDB from the acute to the stable phase of stroke. Logistic regression analysis found dysphagia to be the best independent predictor of AHI reduction of > 50% from baseline (odds ratio, 13.4; 95% confidence interval, 3.3 to 39.6; p = 0.001). CONCLUSION: The present study shows significant improvement in the number obstructive apneic events occurring in the stable phase of a first-ever ischemic stroke in patients with transient pharyngeal muscle alterations secondary to the neurologic lesion.

Inhaled steroids improve quality of life in patients with steady-state bronchiectasis.

BACKGROUND: The effects of inhaled steroids upon the quality of life of patients with bronchiectasis remain unknown. STUDY OBJECTIVE: To analyze the effect of inhaled fluticasone propionate (FP) for 6 months upon the clinical, functional, microbiological and outcome parameters of patients with steady-state bronchiectasis not due to cystic fibrosis, and its repercussions for patient health-related quality of life (HRQoL). DESIGN: Prospective, randomized, double-blind (for effective doses) study. PATIENTS AND INTERVENTIONS: The diagnosis of bronchiectasis was made by high-resolution computed tomography. Ninety-three patients (mean age: 68.5 [8.4]) were randomized to receive 250 microg bid, 500 microg bid or no treatment with inhaled FP for 6 months. Data were collected at baseline and at 1, 3 and 6 months after the start of treatment. HRQoL was assessed using the validated Spanish version of the St. George's Respiratory Questionnaire. RESULTS: The group administered FP 1000 microg daily showed significant improvement in dyspnea (1.03 [2.1]-1.24 [2.2] points; P = 0.01-0.04), sputum production (P = 0.001), days without cough (P = 0.02) and short-acting beta-2 agonists used (P = 0.01) from the first month of treatment, with no changes in pulmonary function, number or severity of exacerbations, or microbiological profile of the sputum. As a result, an improvement in HRQoL was seen in this group after 3 months of treatment (45.4 [14.2] vs. 40.5 [13.9]; P = 0.01). CONCLUSIONS: Inhalatory FP 500 microg bid is effective from the first month of treatment for controlling the symptoms of patients with steady-state bronchiectasis-thus ensuring a significant improvement in HRQoL.

Continuous positive airway pressure treatment in sleep apnea prevents new vascular events after ischemic stroke.

STUDY OBJECTIVES: A study was made of the role of continuous positive airway pressure (CPAP) treatment in the prevention of new vascular events following ischemic stroke or transient ischemic attack. DESIGN: Prospective study. PATIENTS AND INTERVENTIONS: Demographic data, vascular risk factors, clinical manifestations associated to sleep apnea-hypopnea syndrome, and neurologic parameters were recorded in a group of patients presenting with acute ischemic stroke at least 2 months previously. A polygraphic study was carried out 2 months after the acute episode in all patients, with the prescription of CPAP in the event of an apnea-hypopnea index (AHI) > or = 20. Two groups were defined: patients who could tolerate CPAP (group 1), and patients who could not tolerate CPAP after 1 month of initial adaptation (group 2). Patients with an AHI < 20 were excluded. The incidence of new vascular events was evaluated throughout follow-up (18 months) in all patients, with an analysis of the role of CPAP in protecting the patients against such events. RESULTS: Ninety-five patients were studied. Fifty-one patients (53.7%; mean age, 72.7 +/- 9.4 years [+/- SD]) presented with an AHI > or = 20, and 15 patients (29.4%) tolerated CPAP. The incidence of new vascular events was greater in group 2 (6.7%) vs group 1 (36.1%; long-rank, p = 0.03). Intolerance of CPAP increased the probability of a new vascular event fivefold (odds ratio, 5.09) adjusted for other vascular risk factors and neurologic indexes. CONCLUSIONS: We concluded that CPAP treatment during 18 months in patients with an AHI > or = 20 afforded significant protection against new vascular events after ischemic stroke.

Quality-of-life determinants in patients with clinically stable bronchiectasis.

STUDY OBJECTIVE: To determine the most important variables influencing health-related quality of life (HRQL) in patients with clinically stable bronchiectasis (SB). DESIGN: Cross-sectional study. PATIENTS AND INTERVENTIONS: A total of 86 patients (mean age, 69.5 years; SD, 8.9 years; 64% male) with SB were included. Data were collected on general patient characteristics, symptoms, laboratory findings, the extent of bronchiectasis, functional variables, medication in acute or stable phases, and the number of exacerbations. All patients completed the St. George Respiratory Questionnaire (SGRQ). Univariate and multivariate analyses were performed to identify the variables significantly influencing HRQL in these patients. RESULTS: Different clinical parameters (sputum, dyspnea, cough, and wheezing), spirometric variables, and laboratory parameters (fibrinogen), as well as the extent of bronchiectasis, medication, and the number of exacerbations were significantly correlated to the total questionnaire score, although only dyspnea (r2 = 0.43, p < 0.0001), FEV1 (r2 = 0.33, p < 0.0001), and daily sputum production (r2 = 0.2, p < 0.004) were independently correlated to the total score, globally explaining 55% of the total score variability. Systemic steroid treatment of exacerbations (r2 = 0.17, p < 0.028) and the habitual presence of coughing (r2 = 0.22, p < 0.004) and wheezing (r2 = 0.16, p < 0.013) were in turn independently correlated to the activity and symptoms subscales, respectively. CONCLUSION: Dyspnea, FEV1, and sputum production are the strongest conditioning factors of HRQL in patients with clinically SB.